弥漫性中线胶质瘤中HIST1H3B/C与H3F3A K27M突变的预后意义受患者年龄影响
该系统综述纳入26项研究,共102例H3.1与529例H3.3 K27M突变弥漫性中线胶质瘤患者。儿童中H3.3突变较H3.1总生存更短(中位OS 10.1 vs 14.2个月,p<0.001),成人中H3.3则较H3.1生存延长(中位OS 14.4 vs 1.7个月,p=0.019),提示预后受年龄调控。
要点
- 儿童H3.3突变者中位OS 10.1个月,较H3.1的14.2个月更短(p<0.001)。
- 成人H3.3突变者中位OS 14.4个月,较H3.1的1.7个月延长(p=0.019)。
- H3.1突变更常见于较年轻患者。
核心结论
- H3.1与H3.3 K27M突变在弥漫性中线胶质瘤中的预后受患者年龄调控。
- 作者认为对新诊断弥漫性中线胶质瘤常规行H3K27M突变基因分型可能进一步分层这些难治性肿瘤患者。
研究设计与样本
- 检索PubMed与Web of Science,纳入具有H3K27M基因型个体患者数据的弥漫性中线胶质瘤研究,共26项研究。
- 采用Kaplan-Meier分析与Cox回归模型在各亚组中分析H3.1与H3.3突变的生存。
主要发现
- 共纳入102例H3.1突变与529例H3.3突变弥漫性中线胶质瘤患者。
- H3.1突变更常见于较年轻患者。
- 儿童人群中,H3.3突变者中位OS为10.1个月,H3.1阳性者为14.2个月(p<0.001),多因素Cox分析进一步证实。
- 成人患者中,H3.3突变者中位OS为14.4个月,H3.1突变者为1.7个月(p=0.019)。
临床怎么用
- 作者认为对新诊断弥漫性中线胶质瘤常规行H3K27M突变基因分型可能进一步分层这些难治性肿瘤患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Diffuse midline gliomas (DMGs) are infiltrative midline gliomas harboring H3K27M mutations and are generally associated with poor outcomes. H3K27M mutations include mutations in HIST1H3B/C (H3.1), HIST2H3B/D (H3.2), or H3F3A (H3.3) genes. It is still unclear whether these mutations each portend a universally poor prognosis, or if there are any factors which modulate outcome. The main objective of this study was to study overall survival (OS) of H3.1 versus H3.3 K27M-mutant DMGs in pediatric and adult patients. METHODS: PubMed and Web of Science were searched, and we included studies if they have individual patient data of DMGs with available H3K27M genotype. Kaplan-Meier analysis and Cox regression models were used to analyze the survival of H3.1 and H3.3 mutations in each subgroup. RESULTS: We included 26 studies with 102 and 529 H3.1 and H3.3-mutant DMGs, respectively. The H3.1 mutation was more commonly seen in younger age. In pediatric population, H3.3 mutation conferred a shorter survival (median OS of 10.1 vs 14.2 months; p < 0.001) in comparison to H3.1-positive patients, which was further confirmed in the multivariate Cox analysis. Conversely, H3.3 was associated with a prolonged survival in adult patients as compared with H3.1 mutation (median OS of 14.4 vs 1.7 months; p = 0.019). CONCLUSION: We demonstrated that the prognosis of H3.1 and H3.3 K27M mutation in DMG patients is modulated by patient age. Routine H3K27M mutation genotyping in newly diagnosed DMGs may further stratify patients with these difficult tumors.
引用
- Vuong HG, Ngo TNM, Le HT, et al. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age. J Neurooncol. 2022. PMID: 35606633. doi:10.1007/s11060-022-04027-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。